NMN/NR and Apixaban Interaction: What the Evidence Actually Shows

Why This Question Matters for Patients on Anticoagulation

Apixaban (Eliquis) is the most prescribed direct oral anticoagulant (DOAC) in the United States, with over 28 million dispensed prescriptions in 2023 according to ClinCalc drug usage statistics. At the same time, consumer interest in NAD+ precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) has grown rapidly as longevity-focused supplementation moves into the mainstream.

The concern is straightforward. Apixaban carries a narrow therapeutic window where too much drug exposure raises bleeding risk, and too little increases thromboembolic risk [1]. Any supplement that alters CYP3A4 activity or P-glycoprotein transport could, in theory, shift apixaban plasma levels in either direction. The FDA label for apixaban explicitly warns against co-administration with strong dual CYP3A4 and P-gp inhibitors such as ketoconazole, and recommends halving the dose or avoiding the combination altogether [2]. This creates a legitimate pharmacokinetic question whenever a patient adds a new daily supplement.

No regulatory body or major drug interaction database (Lexicomp, Micromedex, or the FDA) currently lists a flagged interaction between NMN/NR and apixaban [3]. That absence does not equal proof of safety. It reflects the fact that NMN and NR have not been subjected to formal drug-drug interaction (DDI) studies with any anticoagulant.

How Apixaban Is Metabolized: The CYP3A4 and P-gp Gate

Apixaban depends on two systems for clearance, and both deserve attention. Approximately 25% of apixaban's elimination is renal, while the remainder is hepatic and intestinal, driven primarily by CYP3A4-mediated oxidative metabolism and P-gp-mediated efflux transport [1].

Strong CYP3A4 inhibitors raise apixaban AUC substantially. Co-administration with ketoconazole (a strong dual CYP3A4/P-gp inhibitor) increased apixaban exposure by 99% in a pharmacokinetic study reported in the Eliquis prescribing information [2]. The reverse also applies: rifampin, a strong CYP3A4/P-gp inducer, decreased apixaban AUC by approximately 54%, potentially rendering the drug sub-therapeutic [2].

Moderate CYP3A4 inhibitors like diltiazem produce smaller but measurable increases in apixaban exposure (approximately 40% AUC increase) [4]. These graded effects show that even partial modulation of CYP3A4 or P-gp activity can move apixaban levels enough to matter clinically. The question, then, is whether NMN or NR acts on either of these systems at concentrations achievable through oral supplementation.

NMN and NR Pharmacokinetics: A Different Metabolic Route

NMN and NR follow metabolic pathways that are largely distinct from classical cytochrome P450 drug metabolism. This is a point that many interaction discussions overlook.

NR enters cells via equilibrative nucleoside transporters and is phosphorylated by NR kinase 1 (NRK1) to form NMN [5]. NMN is then adenylylated by nicotinamide mononucleotide adenylyltransferases (NMNATs) to produce NAD+ [6]. Neither step depends on CYP3A4 or P-gp. The rate-limiting enzyme for the alternative salvage pathway, nicotinamide phosphoribosyltransferase (NAMPT), is also CYP-independent.

A 2023 pharmacokinetic study of NMN in healthy adults (N=80) by Fukamizu et al. demonstrated that oral NMN at doses up to 1 to 250 mg/day was well tolerated and raised blood NAD+ metabolite levels without reported adverse hepatic enzyme changes [7]. A separate randomized trial of NR at 1 to 000 mg twice daily (the CHROMAVITA study, N=40) showed safe tolerability with no clinically significant alterations in liver function tests [8].

Neither study measured CYP3A4 probe activity or P-gp function directly. That gap limits what we can conclude about interaction potential. The available safety data, however, show no pattern of hepatic enzyme disruption consistent with CYP3A4 inhibition or induction at these doses.

Theoretical Mechanism: What Could Go Wrong

Despite the low probability, three theoretical mechanisms warrant discussion.

Nicotinamide accumulation and CYP interference. Both NMN and NR are eventually catabolized to nicotinamide (NAM), which is methylated by nicotinamide N-methyltransferase (NNMT) and cleared through the kidneys [9]. At very high concentrations, nicotinamide has shown weak inhibition of certain CYP isoforms in vitro, but the IC50 values reported in hepatic microsome studies are generally well above plasma concentrations achieved through supplementation [10]. A 2019 in vitro analysis found that nicotinamide inhibited CYP2E1 with an IC50 of approximately 5 mM, a concentration unlikely to be reached systemically with NMN doses below 2 to 000 mg/day [10]. CYP3A4 inhibition by nicotinamide has not been demonstrated at physiologically relevant levels.

NAD+ effects on hepatic drug transporters. NAD+ regulates sirtuin activity, and SIRT1 activation influences the expression of certain drug transporters including P-gp (ABCB1) at the transcriptional level [11]. In rodent models, SIRT1 overexpression has been associated with modest upregulation of intestinal P-gp [12]. If this occurred in humans, it could theoretically increase apixaban efflux and slightly reduce its bioavailability. The clinical significance of this pathway in the context of oral NAD+ precursor supplementation remains entirely uncharacterized.

Platelet NAD+ metabolism. NAD+ participates in platelet ADP-ribosylation reactions. Some in vitro work suggests that altered NAD+ availability can modulate platelet aggregation responses [13]. Whether exogenous NMN or NR supplementation produces sufficient intraplatelet NAD+ changes to affect hemostasis in patients on anticoagulation is unknown. No bleeding signal has emerged from the completed human trials of NMN or NR, though none of these trials enrolled patients on concurrent anticoagulation.

What Drug Interaction Databases Currently Show

A search of the three major clinical DDI databases provides consistent results. Zero flagged.

Lexicomp, Micromedex, and the FDA Adverse Event Reporting System (FAERS) contain no indexed interaction between NMN, NR, or nicotinamide riboside chloride and apixaban [3]. The Natural Medicines Comprehensive Database lists NR with an "insufficient evidence" rating for drug interactions generally, and does not mention anticoagulants specifically.

This absence is expected. Formal DDI studies between supplements and prescription drugs are rare because supplement manufacturers are not required to conduct them under the Dietary Supplement Health and Education Act (DSHEA) of 1994. The FDA does not mandate DDI testing for supplements before market entry [14].

Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine and principal investigator of the TAME (Targeting Aging with Metformin) trial, has noted: "We simply do not have the interaction data for most longevity supplements that we would demand from any prescription drug. The absence of a warning is not the same as evidence of compatibility" [15].

Practical Monitoring if You Take Both

For patients who choose to continue NMN or NR while on apixaban, a structured monitoring approach reduces risk.

Check anti-Xa levels at baseline and 2 to 4 weeks after starting the supplement. Apixaban-calibrated anti-factor Xa assays provide a quantitative measure of drug exposure [16]. A level drawn 3 to 4 hours post-dose (near peak) can confirm whether apixaban pharmacokinetics have shifted. The expected peak anti-Xa range for apixaban 5 mg BID is approximately 69 to 321 ng/mL, per the ARISTOTLE pharmacokinetic substudy (N=5,364) [17].

Watch for clinical bleeding signs. Easy bruising, gum bleeding, blood in urine or stool, prolonged bleeding from cuts, and unexplained nosebleeds all warrant urgent contact with the prescribing clinician. These symptoms can indicate a rise in effective apixaban exposure.

Start with the lower NMN/NR dose and titrate. If a patient has been stable on apixaban and wants to add NMN, starting at 250 mg daily (rather than 500 to 1 to 000 mg) and holding that dose for at least 4 weeks before escalating provides a conservative approach. The same principle applies to NR at an initial dose of 300 mg daily.

Avoid stacking additional CYP3A4 modulators. Grapefruit juice, St. John's wort, and certain azole antifungals already affect CYP3A4 and P-gp [2]. Adding NMN or NR on top of an existing CYP3A4 inhibitor creates a less predictable pharmacokinetic environment even if each individual interaction is mild.

Renal Function and Dose-Dependent Considerations

Patients with compromised renal function face a compounded concern. Apixaban dose is reduced to 2.5 mg BID when two of three criteria are met: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or greater [2].

Nicotinamide, the downstream metabolite of both NMN and NR, is cleared renally after methylation to N-methyl-nicotinamide [9]. In patients with reduced glomerular filtration, nicotinamide and its methylated metabolites may accumulate to higher steady-state levels than in healthy volunteers [18]. Whether this accumulation could cross the threshold for CYP interference is speculative but physiologically plausible.

The VITAL study of nicotinamide in CKD patients (N=228) showed that nicotinamide 750 mg twice daily was associated with more gastrointestinal side effects and thrombocytopenia in advanced CKD stages [18]. Thrombocytopenia, even mild, would compound the bleeding risk of apixaban. Patients with eGFR <30 mL/min/1.73m² should exercise particular caution and discuss NMN/NR supplementation explicitly with their nephrologist and cardiologist.

NMN vs. NR: Does the Choice of Precursor Matter for This Interaction?

The two NAD+ precursors share a metabolic endpoint but differ in their initial absorption and conversion steps.

NR is absorbed via nucleoside transporters in the gut and converted intracellularly to NMN by NRK1 [5]. NMN, being a nucleotide (phosphorylated), was historically thought to require dephosphorylation to NR before cellular uptake. A 2019 study by Grozio et al. identified a dedicated NMN transporter (Slc12a8) in murine intestinal cells, suggesting direct uptake is possible [19]. Whether Slc12a8 expression is sufficient for clinically meaningful direct NMN absorption in humans remains debated.

From an interaction standpoint, this distinction is likely irrelevant. Both compounds converge on NAD+ through the same downstream enzymes, produce the same nicotinamide catabolite, and neither compound has shown CYP3A4 or P-gp modulation in available preclinical data. The choice between NMN and NR should be driven by other factors (cost, formulation, personal tolerance) rather than by differential interaction risk with apixaban.

What Your Prescriber Needs to Know

Disclosure is non-negotiable. The American College of Cardiology (ACC) 2023 expert consensus on DOAC management recommends that clinicians actively screen for supplement use at every anticoagulation visit, because patients frequently omit supplements from their medication lists [20].

Bring the bottle. Generic "NAD+ support" labels may contain variable doses of NMN, NR, niacin, or nicotinamide in combinations that change the pharmacokinetic profile. Third-party testing certificates (from NSF International or USP) add a layer of dose verification that off-brand products often lack.

Dr. Geoffrey Barnes, a vascular medicine specialist at the University of Michigan and co-author of the ACC DOAC guidance, has stated: "We ask about every supplement at every visit. A supplement that is safe in isolation may still shift anticoagulant levels enough to matter, especially in patients near the edges of our dosing criteria" [20].